SAM analogues and their applications as hydroxyethyl donors, hydroxyethylation of methyltransferase mutants, and the enzymatic synthesis of troxerutin.

By developing a cyclic enzyme cascade reaction of SAM analogs and methyltransferase mutants, the problems of water solubility and metabolic stability of natural products and small molecule drugs were solved, achieving efficient and selective hydroxyethylation modification, simplifying the synthesis process and improving bioavailability.

CN123106799APending Publication Date: 2026-11-17TIANJIN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611127522.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-07-28
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

In existing technologies, natural products and small molecule drugs suffer from problems such as poor water solubility, low metabolic stability, and weak target specificity. Chemical synthesis of hydroxyethyl modification has limitations such as harsh reaction conditions, poor selectivity, and low chiral resolution efficiency, and there is a lack of effective hydroxyethyl donors.

Method used

Develop SAM analogs as hydroxyethyl donors, combine them with methyltransferase mutants, and perform hydroxyethylation modification through a cyclic enzyme cascade reaction, including directed mutation and cascade catalysis of specific methyltransferases, to achieve hydroxyethylation modification of natural products and small molecules.

Benefits of technology

It enables the targeted hydroxyethylation of natural products and small molecules, improving molecular solubility, target adaptability and biocompatibility, simplifying the synthesis process, avoiding the side reactions and toxic side effects of chemical methods, and providing an efficient and controllable biocatalytic tool.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106799A_ABST
    Figure CN123106799A_ABST
Patent Text Reader

Abstract

This application provides a SAM analog and its application as a hydroxyethyl donor, the hydroxyethylation reaction of methyltransferase mutants, and the enzymatic synthesis of troxerutin, belonging to the field of biosynthetic technology. The SAM analog has the structure shown in Formula (I): Formula (I); this SAM analog can directionally transfer hydroxyethyl to the nucleophilic site (such as oxygen, nitrogen, sulfur, or carbon atom) of the substrate under the catalysis of methyltransferase. Compared to natural SAM, it overcomes the limitations of traditional methyltransfer reactions, effectively achieving hydroxyethylation modification of natural products and small molecule compounds. This characteristic makes it a technical means for developing novel molecular tools and reconstructing specific metabolic pathways, providing molecular editing capabilities for chemical biology and synthetic biology research.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application relates to the field of biosynthesis, and in particular to a SAM analog and its application as a hydroxyethyl donor, the hydroxyethylation reaction of methyltransferase mutants, and the enzymatic synthesis of troxerutin. Background Technology

[0002] While natural products (flavonoids, polyphenols, etc.) possess unique biological activities, they generally suffer from inherent defects such as poor water solubility, low metabolic stability, and weak target specificity, leading to insufficient bioavailability and a high risk of toxic side effects. Similar challenges exist in the design of small molecule drugs. For example, excessive lipophilicity may increase metabolic stress and toxicity, while an excessive number of polar functional groups can weaken the molecule's membrane permeability, resulting in decreased bioavailability. Furthermore, easily metabolized structural units in the molecule (such as aniline and ester bonds) can rapidly transform into ineffective or harmful products, hindering further development. Functional group modification (such as alkylation) is a core strategy for optimizing these issues. Hydroxyethyl (HOEt-) compounds, due to their conformational flexibility, hydrogen bonding activity, and polar-hydrophobic balance, can effectively improve molecular solubility, target adaptability, and biocompatibility, demonstrating significant potential for application in medicinal chemistry.

[0003] Currently, hydroxyethyl modification mainly relies on chemical synthesis, but it has limitations such as harsh reaction conditions, poor selectivity, low chiral resolution efficiency, and the easy generation of complex byproducts from substrates with multiple active sites. Biocatalysis, on the other hand, provides a new approach for hydroxyethyl modification due to its mild conditions, high selectivity, and environmental friendliness. However, no hydroxyethyl donor has been found yet, so it is necessary to develop a SAM analog as a hydroxyethyl donor for hydroxyethylation modification. Summary of the Invention

[0004] In view of this, in order to at least partially solve the aforementioned technical problems, this application provides SAM analogs and their use as hydroxyethyl donors, hydroxyethylation reactions of methyltransferase mutants, and the enzymatic synthesis of troxerutin.

[0005] According to one embodiment of this application, a SAM analogue is provided, having the structure shown in formula (I):

[0006] Formula (I).

[0007] According to an embodiment of another aspect of this application, an application of a SAM analog as a hydroxyethyl donor is provided.

[0008] According to another embodiment of this application, a methyltransferase mutant is provided, comprising:

[0009] The CNMT methyltransferase mutant, with threonine at position 71 mutated to valine and threonine at position 189 mutated to serine, has its amino acid sequence in GenBank accession number BAB71802.1.

[0010] The methyltransferase OsNOMT, which has a leucine mutation at position 284 to alanine, has its amino acid sequence accessed in GenBank as BAM13734.1.

[0011] The methyltransferase MpOMT4 is a wild-type methyltransferase with methionine at position 159 mutated to valine, serine at position 142 mutated to valine, and tryptophan at position 246 mutated to serine. The GenBank accession number for the amino acid sequence of wild-type methyltransferase MpOMT4 is AAR09602.1.

[0012] The methyltransferase GerMIII, with tyrosine at position 212 mutated to tryptophan and leucine at position 222 mutated to isoleucine, has its amino acid sequence accessed in GenBank as ABB52542.1.

[0013] According to another embodiment of this application, a method for hydroxyethylating a compound is provided, comprising: mixing the compound to be reacted, a SAM analog, a methyltransferase mutant, and a pH buffer to obtain a reaction raw material solution; subjecting the reaction raw material solution to a light-protected reaction to obtain a reaction mixture; and sequentially quenching and purifying the reaction mixture to obtain a hydroxyethylated compound; preferably, the light-protected reaction temperature is 20-40°C, and the light-protected reaction time is 15-25 h; the pH buffer is at least one selected from tris(hydroxymethyl)aminomethane hydrochloride solution, alkali metal phosphate solution, alkali metal borate solution, and alkali metal carbonate solution.

[0014] According to another embodiment of this application, a method for hydroxyethylation using a cyclic enzyme cascade reaction is provided, comprising: simultaneously performing steps 1) and 2) in the same reaction system, 1) reacting SAH with a hydroxyethylating agent catalyzed by a halide methyltransferase mutant to generate a SAM analog; 2) reacting the SAM analog with an acceptor substrate under the action of a methyltransferase mutant or a methyltransferase to obtain a hydroxyethylated acceptor product and SAH; wherein the SAH obtained in step 2) is recycled for the reaction in step 1).

[0015] According to another embodiment of this application, a method for synthesizing troxerutin is provided, comprising: mixing a first portion of SAH, a hydroxyethylating agent, a first portion of a halide methyltransferase mutant, a reducing agent, a first methyltransferase mutant, and quercetin to perform a first cascade reaction to obtain a first reaction solution containing 7-position hydroxyethylated quercetin; adding a second portion of SAH, a second portion of a halide methyltransferase mutant, and a second methyltransferase mutant to the first reaction solution containing 7-position hydroxyethylated quercetin to perform a second cascade reaction to obtain a second reaction solution containing di-position hydroxyethylated quercetin; adding a third portion of SAH, a third portion of a halide methyltransferase mutant, and a third methyltransferase mutant to the second reaction solution containing di-position hydroxyethylated quercetin to perform a third cascade reaction to obtain a third reaction solution containing 3-position hydroxyethylated quercetin; and sequentially modifying the 3-position hydroxyethylated quercetin in the third reaction solution by glucosylation and rhamnosylation to obtain the troxerutin.

[0016] According to embodiments of this application, this SAM analog can directionally transfer hydroxyethyl groups to nucleophilic sites (such as oxygen, nitrogen, sulfur, or carbon atoms) of a substrate under the catalysis of methyltransferases. Compared to natural SAMs, it overcomes the limitations of traditional methyltransfer reactions, enabling efficient hydroxyethylation modification of natural products and small molecule compounds. This characteristic makes it a technical means for developing novel molecular tools and reconstructing specific metabolic pathways, providing molecular editing capabilities for chemical biology and synthetic biology research. Detailed Implementation

[0017] The embodiments of this application will be described below. However, it should be understood that these descriptions are exemplary only and are not intended to limit the scope of this application. In the following detailed description, many specific details are set forth to provide a thorough understanding of the embodiments of this application for ease of explanation. However, it will be apparent that one or more embodiments may be implemented without these specific details. Furthermore, descriptions of well-known structures and technologies are omitted in the following description to avoid unnecessarily obscuring the concepts of this application.

[0018] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of this application. The term "comprising" as used herein indicates the presence of features, steps, or operations, but does not exclude the presence or addition of one or more other features.

[0019] When using expressions such as "at least one of A, B and C", they should generally be interpreted in accordance with the meaning that is commonly understood by those skilled in the art (e.g., "a system having at least one of A, B and C" should include, but is not limited to, a system having A alone, a system having B alone, a system having C alone, a system having A and B, a system having A and C, a system having B and C, and / or a system having A, B and C, etc.).

[0020] In this application, the term "cyclic enzyme cascade" refers to a closed-loop reaction system consisting of two or more enzymes coupled together. In this system, after a specific substance (such as a coenzyme, substrate, or intermediate) is consumed / converted by the first enzyme, its product immediately becomes the substrate of the second enzyme and is reduced or regenerated to its initial state.

[0021] In this application, the term "methyltransferase" refers to a transferase that specifically catalyzes the transfer of a methyl (-CH3) or alkyl group from a donor molecule to an acceptor substrate. Based on structural biology characteristics, methyltransferases are mainly classified into the following subclasses: Class I methyltransferases containing a Rossmann fold core domain for binding S-adenosylmethionine (SAM) or its analogues; Class II methyltransferases containing a SET domain; and membrane-bound Class III methyltransferases. In this application, unless otherwise specified, the term "methyltransferase" refers to a natural enzyme possessing the structural characteristics of Class I and whose catalytic process primarily involves and depends on S-adenosylmethionine (SAM) as a methyl donor.

[0022] In this application, the term "SAM Analogs" refers to non-natural compounds in which the natural methyl group (-CH3) attached to the thioonium center (or selenoonium, tellurium center) of the natural S-adenosine-L-methionine (SAM) is replaced with a hydroxyethyl group.

[0023] In this application, the term "halide methyltransferase (HMT)" refers to a transferase belonging to the Class I methyltransferase subclass that structurally contains a Rossmann fold core domain for binding the adenosine backbone. For example, AclHMT, whose amino acid sequence is derived from Aspergillus clavatus (gene bank number: EAW10780.1).

[0024] In this application, the term "enzyme mutant," also known as engineered enzyme or artificially modified enzyme, such as methyltransferase mutant or halide methyltransferase mutant, refers to a non-natural protein with specific catalytic activity obtained by modifying the amino acid sequence of a specific parental enzyme or wild-type natural enzyme at one or more points through genetic engineering or protein engineering. The modification includes, but is not limited to, the substitution, deletion, addition, or combination thereof of one or more amino acid residues.

[0025] In this application, the term "hydroxyethylating agent" refers to a class of electrophilic chemical substances that can introduce hydroxyethyl (-CH2CH2OH) into a target molecule (substrate) through a chemical reaction in organic chemical synthesis.

[0026] In realizing the concept of this application, it was discovered that S-adenosyl-L-methionine (SAM) and SAM-dependent methyltransferases (MTs) are the most widespread catalytic systems in nature, through typical S... N 2. The nucleophilic attack mechanism transfers methyl groups from SAM to acceptor substrates such as proteins, nucleic acids, and small metabolic molecules, producing the byproduct S-adenosine-L-homocysteine ​​(SAH). Halide methyltransferases (HMTs) are a special class of methyltransferases that have been found to catalyze the reaction of SAH with haloalkanes to generate SAM and its analogues. Therefore, SAM and its analogues can be developed as donors for hydroxyethylation modification using the above method.

[0027] Specifically, according to one aspect of this application, a SAM analogue is provided, having the structure shown in formula (I):

[0028] Formula (I).

[0029] According to embodiments of this application, this SAM analog can directionally transfer hydroxyethyl groups to nucleophilic sites (such as oxygen, nitrogen, sulfur, or carbon atoms) of a substrate under the catalysis of methyltransferases. Compared to natural SAMs, it overcomes the limitations of traditional methyltransfer reactions, enabling efficient hydroxyethylation modification of natural products and small molecule compounds. This characteristic makes it a technical means for developing novel molecular tools and reconstructing specific metabolic pathways, providing molecular editing capabilities for chemical biology and synthetic biology research.

[0030] According to embodiments of this application, an application of a SAM analog as a hydroxyethyl donor is provided.

[0031] According to embodiments of this application, the SAM analog transforms the introduction of hydroxyethyl groups from an uncontrollable, broad-spectrum electrophilic substitution into a directional, programmable transfer process similar to natural SAM methyl transfer. Its hydrophilicity, bipolar hydrogen bond activity, and polar-hydrophobic properties enable synergistic optimization of solubility, target binding compatibility, and metabolic stability while achieving site-specific modification. It also avoids the risks of residual highly toxic reagents and the generation of unknown toxic impurities in side reactions associated with chemical methods. When docking with selectively modified methyltransferases, it can precisely achieve multi-step controllable single / multi-site hydroxyethylation of multi-active site natural products such as flavonoids and alkaloids, and can directionally synthesize troxerutin and its analogues. This provides a universal, safe, and cascade-scalable biocatalytic tool for the targeted hydroxyethyl derivatization of other lead compounds.

[0032] According to an embodiment of this application, a methyltransferase mutant is provided, comprising:

[0033] The CNMT mutant of methyltransferase (CNMT(T71V / T189S)) has a 71st threonine mutation to valine and a 189th threonine mutation to serine. The GenBank accession number for the amino acid sequence of the wild-type methyltransferase CNMT is BAB71802.1.

[0034] The methyltransferase OsNOMT (OsNOMT(L284A)) with a leucine mutation at position 284 is described in GenBank accession number BAM13734.1.

[0035] The methyltransferase MpOMT4 (MpOMT4(M159V / S142V / W246S)) is a methyltransferase with methionine at position 159 mutated to valine, serine at position 142 mutated to valine, and tryptophan at position 246 mutated to serine. The amino acid sequence of the wild-type methyltransferase MpOMT4 is available in GenBank under accession number AAR09602.1.

[0036] The methyltransferase GerMIII (GerMIII(Y212W / L222I)) is a methyltransferase with tyrosine at position 212 mutated to tryptophan and leucine at position 222 mutated to isoleucine. The amino acid sequence of the wild-type methyltransferase GerMIII is available in GenBank under accession number ABB52542.1.

[0037] According to embodiments of this application, CNMT (T71V / T189S), OsNOMT (L284A), MpOMT4 (M159V / S142V / W246S), and GerMIII (Y212W / L222I) mutants were constructed by targeted mutation of local sites in the active pocket of wild-type methyltransferases, making them highly efficient hydroxyethyltransferases. Through HMT-MTs cascade reactions, highly efficient regioselective hydroxyethylation modification of tetrahydroisoquinoline and substrates with multiple reaction sites, such as juglansine, quercetin, quercetin glucoside, and rutin, was achieved.

[0038] According to embodiments of this application, a method for hydroxyethylating a compound is provided, comprising: mixing the compound to be reacted, a SAM analog, a methyltransferase mutant, and a pH buffer to obtain a reaction raw material solution; subjecting the reaction raw material solution to a light-protected reaction to obtain a reaction mixture; and sequentially quenching and purifying the reaction mixture to obtain a hydroxyethylated compound; preferably, the light-protected reaction temperature is 20-40°C, and the light-protected reaction time is 15-25 h; the pH buffer is at least one selected from tris(hydroxymethyl)aminomethane hydrochloride solution, alkali metal phosphate solution, alkali metal borate solution, and alkali metal carbonate solution.

[0039] According to embodiments of this application, the temperature for the light-protected reaction can be 20°C, 25°C, 30°C, 35°C, or 40°C, but is not limited to the listed values; other unlisted values ​​within this range are also applicable. Alternatively, it can be within a range consisting of any two values, such as 20~30°C, 31~40°C, etc.

[0040] According to embodiments of this application, the light-protected reaction time can be 15h, 16h, 18h, 20h, 22h, or 25h, but is not limited to the listed values; other unlisted values ​​within this range are also applicable. Alternatively, it can be within a range consisting of any two values, such as 15~20h, 21~25h, etc.

[0041] According to embodiments of this application, this method can directly mix SAM analogs, methyltransferase mutants, and the compound to be reacted to achieve hydroxyethylation of the compound. The process is carried out gently in a pH buffer at 20–40°C in the dark, effectively suppressing non-enzymatic degradation of SAM analogs and substrate oxidation side reactions. This achieves direct single / multi-site hydroxyethylation of the compound, avoiding the random site, over-substitution, and racemization problems common in chemical methods. The resulting product is dominated by a single or a few clearly defined isomers, simplifying the subsequent purification process and improving product purity.

[0042] According to an embodiment of this application, a method for hydroxyethylation using a cyclic enzyme cascade reaction is provided, comprising: simultaneously performing steps 1) and 2) in the same reaction system, 1) reacting SAH with a hydroxyethylating agent catalyzed by a halide methyltransferase mutant to generate a SAM analog; 2) reacting the SAM analog with an acceptor substrate under the action of a methyltransferase mutant or a methyltransferase to obtain a hydroxyethylated acceptor product and the SAH from step 1); wherein the SAH obtained in step 2) is recycled for the reaction in step 1).

[0043] According to embodiments of this application, by constructing a cyclic enzyme cascade reaction of SAM analogs, methyltransferase mutants, etc., the preparation of unstable hydroxyethyl donors and site-selective transfer are integrated into the same mild reaction system. This not only effectively avoids the stability problems of pre-synthesized and isolated SAM analogs, but also achieves efficient and economical utilization of cofactors through the cyclic regeneration of SAH. This method simplifies the traditional multi-step synthesis process into a one-step operation, reducing costs and process complexity, and can be flexibly adapted to various methyltransferase mutants. It provides a highly scalable and universal enzymatic synthetic route for the hydroxyethylation modification of a series of natural products and drug lead compounds.

[0044] According to an embodiment of this application, the halide methyltransferase mutant is a halide methyltransferase AclHMT (AclHMT(W27F / P8L / V265W)) with tryptophan at position 27 mutated to phenylalanine, proline at position 8 mutated to leucine, and valine at position 265 mutated to tryptophan. The amino acid sequence of the wild-type halide methyltransferase AclHMT has the GenBank accession number EAW10780.1.

[0045] According to the embodiments of this application, the mutant mutates the active site and key sites (W27F, P8L, V265W) of the substrate channel of wild-type AclHMT. These mutations together reprogram HMT from its natural haloalkane methylation function to a highly efficient synthase of SAM analogs. Its catalytic efficiency and tolerance to hydroxylation reagents are effectively improved, thereby achieving rapid and steady-state conversion of SAH to SAM analogs in the cascade reaction. This provides a continuous supply of sufficient and fresh hydroxyethyl donors for the downstream methyltransferase mutant, ensuring the catalytic flux and operational stability of the entire cyclic enzyme cascade.

[0046] According to the embodiments of this application, when the receptor substrate is rutin or quercetin-3-O-glucoside, the methyltransferase is COMT, and its amino acid sequence has the GenBank accession number BAB71802.1.

[0047] When the receptor substrate is juglansine, the methyltransferase mutant is the methyltransferase OsNOMT with leucine at position 284 mutated to alanine. The GenBank accession number for the amino acid sequence of the wild-type methyltransferase OsNOMT is BAM13734.1.

[0048] When the receptor substrate is tetrahydroisoquinoline alkaloid, the methyltransferase mutant is the CNMT methyltransferase mutant with threonine at position 71 mutated to valine and threonine at position 189 mutated to serine. The GenBank accession number for the amino acid sequence of the wild-type methyltransferase CNMT is BAB71802.1.

[0049] When the receptor substrate is quercetin, the methyltransferase mutant is OsNOMT, which has a leucine-to-alanine mutation at position 284. The GenBank accession number for the amino acid sequence of the wild-type methyltransferase OsNOMT is BAM13734.1. Alternatively, it is MpOMT4, which has a methionine-to-valine mutation at position 159, a serine-to-valine mutation at position 142, and a tryptophan-to-serine mutation at position 246. The GenBank accession number for the amino acid sequence of the wild-type methyltransferase MpOMT4 is AAR09602.1.

[0050] When the receptor substrate is quercetin-3-O-glucoside, the methyltransferase mutant is GerMIII, which has a tyrosine mutation at position 212 replaced by tryptophan and a leucine mutation at position 222 replaced by isoleucine. The GenBank accession number for the amino acid sequence of the wild-type methyltransferase GerMIII is ABB52542.1.

[0051] According to embodiments of this application, by designing specific methyltransferases for substrates with diverse structures, modular and programmable selective hydroxyethylation, which is difficult to achieve through traditional chemical synthesis, can be realized. Specifically, for the glycosylated structures of rutin and quercetin glycosides, the single phenolic hydroxyl group of juglans oleracea, the polyphenolic hydroxyl network of quercetin, and the nitrogen-containing heterocycle of tetrahydroisoquinoline, enzyme catalysts such as COMT, OsNOMT (L284A), MpOMT4 (M159V / S142V / W246S), and CNMT (T71V / T189S) can be used to precisely guide the hydroxyethyl group to a predetermined active site. This one-substrate-one-enzyme matching strategy can effectively prepare high-purity hydroxyethylated derivatives with well-defined and singular structures, thus providing a key high-quality compound library for in-depth structure-activity relationship studies and innovative drug development.

[0052] According to an embodiment of this application, a method for synthesizing troxerutin is provided, comprising: mixing a first portion of SAH, a hydroxyethylating agent, a first portion of a halide methyltransferase mutant, a reducing agent, a first methyltransferase mutant, and quercetin to perform a first cascade reaction to obtain a first reaction solution containing 7-position hydroxyethylated quercetin; adding a second portion of SAH, a second portion of a halide methyltransferase mutant, and a second methyltransferase mutant to the first reaction solution containing 7-position hydroxyethylated quercetin to perform a second cascade reaction to obtain a second reaction solution containing di-position hydroxyethylated quercetin; adding a third portion of SAH, a third portion of a halide methyltransferase mutant, and a third methyltransferase mutant to the second reaction solution containing di-position hydroxyethylated quercetin to perform a third cascade reaction to obtain a third reaction solution containing 3-position hydroxyethylated quercetin; and sequentially modifying the 3-position hydroxyethylated quercetin in the third reaction solution by glucosylation and rhamnosylation to obtain troxerutin.

[0053] Preferably, glucosylation modification is achieved by enzyme catalysis, such as glycosyltransferase Sb3GT1; rhamnosylation modification is achieved by enzyme catalysis, such as rhamnosyltransferase FeF3G6"RhaT and CiRhaT-GD4x.

[0054] According to embodiments of this application, this method provides a precise, programmable enzymatic total synthesis route for the preparation of troxerutin. This method can progressively and site-specifically introduce three hydroxyethyl groups onto the quercetin backbone. Each step utilizes a corresponding methyltransferase mutant to ensure regioselectivity of the reaction, thereby precisely constructing the target intermediate. Subsequently, enzymatically catalyzed glucosylation and rhamnosylation are performed, ultimately assembling the structurally correct troxerutin in a one-pot process. The entire process is conducted under mild conditions, avoiding the protection / deprotection steps, use of toxic reagents, and isomer contamination problems common in chemical methods. It achieves green and precise synthesis from simple raw materials to complex glycoside molecules, providing a novel biocatalytic model for the preparation of similar multi-modified natural products.

[0055] According to the embodiments of this application, the first methyltransferase mutant is the methyltransferase OsNOMT with leucine at position 284 mutated to alanine; the second methyltransferase mutant is the methyltransferase ROMT9 with methionine at position 184 mutated to glycine and tryptophan at position 271 mutated to histidine, and the NCBI accession number of the amino acid sequence of the wild-type methyltransferase ROMT9 is NP_001390411.1; the third methyltransferase mutant is the methyltransferase MpOMT4 with methionine at position 159 mutated to valine, serine at position 142 mutated to valine, and tryptophan at position 246 mutated to serine.

[0056] According to embodiments of this application, an ordered, site-specific enzyme catalytic system was constructed by designing and combining three complementary methyltransferase mutants. This system can accurately identify and distinguish intermediates on the quercetin backbone whose structures change continuously after the previous modification, thereby irreversibly and stepwise introducing the three hydroxyethyl groups sequentially into the predetermined phenolic hydroxyl sites. This one-step-one-enzyme-one-site matching strategy ensures the regioselectivity and step controllability of the multi-step cascade reaction, effectively avoiding site competition, over-modification, or the generation of byproducts. Ultimately, it can obtain the three-hydroxyethylated quercetin key intermediate, laying the foundation for the subsequent glycosylation step to synthesize structurally correct troxerutin.

[0057] According to an embodiment of this application, the halide methyltransferase mutant is a halide methyltransferase AclHMT with tryptophan at position 27 mutated to phenylalanine, proline at position 8 mutated to leucine, and valine at position 265 mutated to tryptophan.

[0058] According to the embodiments of this application, by using hydroxyethylating reagents, halide methyltransferase AclHMT mutants, methyltransferase mutants, and combining dithiothreitol as a reducing agent, the efficiency and specificity of the hydroxyethylation reaction are effectively improved. The reaction substrate and intermediates are stabilized by the reducing environment, thereby enhancing the overall yield and purity of the product synthesis.

[0059] The following will further explain the solution of this application with reference to specific embodiments. Unless otherwise stated, the reagents used in the following embodiments are all commercially available reagents.

[0060] Preparation Example:

[0061] In the following embodiments, HMT is preferably AclHMT, MTs are preferably CNMT, OsNOMT, ROMT9, MpOMT4, GerMIII, and COMT, glucosyltransferase is preferably Sb3GT1, and rhamnosyltransferase is preferably FeF3G6"RhaT and CiRhaT-GD4x. The aclhmt gene is derived from Aspergillus clavatus (GenBank: EAW10780.1), the cnmt gene is derived from Coptis japonica (GenBank: BAB71802.1), the osnomt gene is derived from Oryza sativa (GenBank: BAM13734.1), the romt9 gene is derived from Oryza sativa (NCBI Reference Sequence: NP_001390411.1), and the mpomt4 gene is derived from Mentha x piperita (GenBank: AAR09602.1), germiii gene is derived from Streptomyces sp. KCTC0041BP (GenBank: ABB52542.1), comt gene is derived from Homo sapiens (GenBank: AAA68927.1), sb3gt1 gene is derived from Scutellariabaicalensis (GenBank: QBL54224.1), fef3g6"rhat gene is derived from Fagopyrum esculentum (GenBank: BBF24939.1), and cirhat-gd4x gene is derived from Chrysanthemumindicum (GenBank: UYE98987.1).The aclhmt, cnmt, germiii, sb3gt1, and fef3g6"rhat genes were synthesized by Wuhan Jinkairui Biotechnology Co., Ltd., and after BL21(DE3) codon optimization, they were constructed into the pET28a(+) vector carrying the Kanamycin resistance gene, ultimately yielding the plasmids pET28a(+)-AclHMT, pET28a(+)-CNMT, pET28a(+)-GerMIII, pET28a(+)-Sb3GT1, and pET28a(+)-FeF3G6"RhaT; the osnomt and romt9 genes were synthesized by Wuhan Jinkairui Biotechnology Co., Ltd., and after BL21(DE3) codon optimization, they were constructed into the pET28a(+) vector carrying the Kanamycin resistance gene. After optimization, the pET15b(+) vector containing the Ampicillin resistance gene was constructed, resulting in the pET15b(+)-OsNOMT and pET15b(+)-ROMT9 plasmids. The mpont4, comitt, and cirhat-gd4x genes were synthesized by Wuhan Jinkairui Biotechnology Co., Ltd., and after BL21(DE3) codon optimization, they were constructed in the pET19b(+), pET22b(+), and pMAL-c5X vectors containing the Ampicillin resistance gene, respectively, resulting in the pET19b(+)-MpOMT4, pET22b(+)-COMT, and pMAL-c5X-CiRhaT-GD4x plasmids. AclHMT was constructed using the optimal mutant W27F / P8L / V265W, referring to the literature (Chen Q, et al. Mol. Catal. 2023, 550, 113533-113539). ROMT9 was constructed using the optimal mutant M184G / W271H, referring to the literature (Dong M, et al. Chem. Commun. 2025, 61, 19882-19885). CNMT was constructed using the optimal mutant T71V / T189S. OsNOMT was constructed using the optimal mutant L284A. MpOMT4 was constructed using the optimal mutant M159V / S142V / W246S. GerMIII was constructed using the optimal mutant Y212W / L222I. All of these were constructed using computer-aided technology in this invention.

[0062] Example 1: Enzymatic Synthesis of SAM Analogs

[0063] The total volume of the reaction solution, 25 mL, contained 1 mM SAH, 2.5 mM iodoethanol (HOEtI), 100 μM MAclHMT (W27F / P8L / V265W), and 50 mM sodium phosphate buffer (PBS) (pH 7.6), with the remainder replenished with deionized water. The reaction solution was placed in 50 mL centrifuge tubes and reacted at 30 °C and 80 rpm for 60 min on a shaker. An equal volume of 10% trifluoroacetic acid (TFA) aqueous solution was then added to terminate the reaction. After centrifugation at 12000 rpm for 30 min, the supernatant was purified by preparative high-performance liquid chromatography (HPLC) at dual wavelengths of 215 nm and 254 nm. The HPLC elution program was: 0–4 min 0% B, 4.01–24 min 0–15% B, 24.01–29 min 15–95% B, 29.01–33 min 95% B, 33.01–40 min 0% B. The mobile phases were ultrapure water containing 0.1% TFA and acetonitrile, with a flow rate of 3 mL / min. After freeze-drying under vacuum, the product, a SAM analog (9.5 mg, yield 89%), was obtained. The NMR and mass spectrometry data of the SAM analog are as follows: 1 H NMR (800 MHz, D2O) δ 8.42 (d, J=3.0 Hz, 2H), 6.14 (t, J=3.2 Hz, 1H), 4.84–4.81 (m, 1H), 4.61 (q, J=5.8 Hz, 1H), 4.54 (t, J=6.2 Hz, 1H), 4.12–3.97 (m, 5H), 3.74–3.60 (m, 4H), 2.48–2.42 (m, 1H), 2.40–2.34 (m, 1H). 13 C NMR (200 MHz, D2O) δ 170.05,149.93,147.94,144.39,143.50,119.29,90.12,78.69,73.10,72.68,55.94,50.96,44.41,42.98,37.10,24.98.LCMS(ESI)calcd.for C 16 H 25 N6O6S + [M] + 429.1551, obsd.429.1454.

[0064] Example 2: Cascade catalysis of AclHMT (W27F / P8L / V265W) and CNMT (T71V / T189S) to produce 2-hydroxyethyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline

[0065] Wild-type linderine N-methyltransferase CNMT exhibits relatively weak catalytic activity in the cascade reaction to produce hydroxyethylated products, with a yield of approximately 40% for the 1 mM substrate 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline. Based on analysis of the CNMT crystal structure (PDB: 6gkv.1), combined with sequence conservation analysis and intelligent computation and recommendations from a bioinformatics website, semi-rational design mutations were performed targeting Y81, T71, E72, T189, and the L205 site in the active pocket, constructing a series of single mutants. After activity testing, the dominant single mutants with enhanced activity were combined to construct six double mutants. Among them, T71V / T189S was the optimal mutant, achieving a conversion rate of 85% for the 1 mM substrate, which is twice that of WT. The conversion rates of the other double mutants to 1 mM substrate under the same experimental conditions were: T71V / L205M: 61%, T71V / L205V: 75%, T71C / L205M: 66%, T71C / L205V: 72%, and T71C / T189S: 63%.

[0066] The cascade reaction activity assay consisted of a 100 μL system containing 100 μM SAH, 2.5 mM HOEtI, 1 mM 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 40 μM purified AclHMT (W27F / P8L / V265W), 80 μM purified CNMT (T71V / T189S), and 100 mM potassium phosphate (KPi) buffer (pH 7.0). After reacting in a 30 °C water bath in the dark for 20 h, an equal volume of 10% TFA aqueous solution was added to quench the reaction, and the mixture was centrifuged at 12000 rpm for 30 min to remove protein precipitate. The supernatant was then analyzed by HPLC using a Shimadzu C18 column (250 mm × 4.6 mm, 5 μm) at dual wavelengths of 254 nm and 280 nm to detect substrate consumption and product formation. The HPLC elution gradient was: 0–4 min 0% B, 4–12 min 0–8% B, 12–22 min 8–16% B, 22.01–25 min 90% B, and 25.01–29 min 0% B. The mobile phases were 25 mM ammonium acetate-formic acid solution (pH 5.4) and acetonitrile, with a flow rate of 1 mL / min. The same reaction system was used to scale up the preparation of the target product. Preparative HPLC was used for separation and purification at a flow rate of 3 mL / min. The purified sample was collected and freeze-dried under vacuum to obtain the product (5.5 mg, yield 79%). The NMR and mass spectrometry data of 2-hydroxyethyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline are as follows: 1H NMR (800 MHz, DMSO-d6) δ 6.65 (s, 1H), 6.62 (s, 1H), 4.52 (s, 1H), 3.69 (d, J=6.3 Hz, 6H), 3.59 (t, J=6.3 Hz, 2H), 3.54 (s, 2H), 2.71 (p, J=4.4, 4.0 Hz, 4H), 2.58 (t, J=6.3 Hz, 2H). 13 C NMR (200 MHz, DMSO-d6) δ 147.19, 146.92, 126.26, 125.70, 111.72, 109.91, 59.96, 58.61, 55.51, 55.47, 55.27, 51.06, 28.01.LCMS (ESI) calcd.for C 13 H 19 NO3[M+H] 1+ 238.1438, obsd.238.1531.

[0067] The reaction formula is as follows:

[0068]

[0069] Example 3: Cascade catalysis of AclHMT (W27F / P8L / V265W) and OsNOMT (L284A) to produce 7-hydroxyethyl quercetin and 7-hydroxyethyl succinate.

[0070] Wild-type naringenin-7-O-methyltransferase OsNOMT exhibits very weak reactivity to quercetin and naringenin, producing no significant products. Only weak molecular ion peaks of the relevant products can be extracted by high-resolution quadrupole time-of-flight mass spectrometry (HR-MS). Since no crystal structure of OsNOMT has been reported, crystal structures of proteins with high homology to OsNOMT were searched using the SWISS-MODEL database for structural analysis. Homology modeling was then performed using the crystal structure of sorghum dichromatin O-methyltransferase SbCOMT (PDB: 4pgh.1), which has 46% sequence similarity. Analysis of the homology model and the SbCOMT catalytic pocket revealed that residues M191, F187, and L284 are close to the methyl group of the cofactor SAM, potentially restricting the introduction of a hydroxyethyl group. Six single mutations (F187A / D, M191A / D, and L284A / G) were rationally designed. Activity tests revealed that L284A showed the most significant activity enhancement, achieving a 70% analytical yield of juglansine and complete conversion of quercetin. F187D and L284G exhibited weak hydroxyethyl activity towards juglansine, with analytical yields of 2% and 4%, respectively. The remaining mutants showed no significant activity towards juglansine.

[0071] The cascade reaction activity assay for juglans regia substrate consisted of a 100 μL system containing 100 μM SAH, 2.5 mM HOEtI, 0.5 mM juglans regia, 40 μM purified AclHMT (W27F / P8L / V265W), 80 μM purified OsNOMT (L284A), and 50 mM Tris-HCl buffer (pH 7.5). The cascade reaction activity assay for quercetin substrate consisted of a 100 μL system containing 150 μM SAH, 2.5 mM HOEtI, 1 mM quercetin, 3 mM dithiothreitol (DTT), 50 μM purified AclHMT (W27F / P8L / V265W), 100 μM purified OsNOMT (L284A), and 50 mM Tris-HCl buffer (pH 7.5). Both reactions were carried out in a 30 ℃ water bath in the dark for 20 h, followed by the addition of an equal volume of anhydrous methanol and standing at -20 ℃ for 30 min to quench the reaction. Protein precipitate was removed by centrifugation at 12000 rpm for 30 min, and the supernatant was analyzed by HPLC. Substrate consumption and product formation were detected using a Shimadzu C18 column (250 mm × 4.6 mm, 5 μm) at dual wavelengths of 215 nm and 260 nm. The HPLC elution gradients for salinomycin substrate were: 0–4 min 0% B, 4–7 min 0–40% B, 7–21 min 40–62% B, 21.01–24 min 100% B, and 24.01–28 min 0% B; the HPLC elution gradients for oak bark substrate were: 0–4 min 0% B, 4–9 min 0–14% B, 9–16 min 14–30% B, 16–27 min 30–36% B, 27.01–30 min 95% B, and 30.01–34 min 0% B. The mobile phases were ultrapure water containing 0.1% TFA and acetonitrile, and the flow rate was 1 mL / min.

[0072] The reaction formula is as follows:

[0073]

[0074] Example 4: Cascade catalysis of AclHMT (W27F / P8L / V265W) and MpOMT4 (M159V / S142V / W246S) to produce 4'-hydroxyethyl quercetin.

[0075] MpOMT4, a flavonoid 4'-O-methyltransferase from peppermint, has been reported as a methyltransferase that specifically catalyzes the conversion of isorhamnetin (3'-methylquercetin) to 3',4'-dimethylquercetin, which may be helpful in the formation of polyhydroxyethylated products. The hydroxyethylation activity of wild-type MpOMT4 on quercetin 4'-OH was tested by a cascade reaction, and HPLC analysis revealed only a trace amount of product (3%). Since the crystal structure of MpOMT4 is currently unknown, its protein structure was predicted using the AlphaFold database for structural analysis. SAM and HOEt-SAM were then docked into the structure using AutoDock to analyze the key amino acids affecting hydroxyethyl inclusion and transfer. Following crystal structure analysis, 12 single mutations were rationally designed targeting residues M159, R190, F155, S142, and F133. By combining these advantageous single mutants, the M159V / S142V double mutant, significantly enhancing hydroxyethylation activity, was constructed. Subsequently, based on the mutation hotspots recommended by the HotSpot Wizard website—F155, I215, W246, and R190—10 triple mutants were constructed on the M159V / S142V double mutant. Activity testing revealed that while the other mutants showed no significant effect, with conversion rates below 5%, M159V / S142V / W246S exhibited excellent hydroxyethylation activity, achieving a substrate conversion rate of 96%.

[0076] The cascade reaction activity assay for quercetin consisted of a 100 μL system containing 200 μM SAH, 2.5 mM HOEtI, 1 mM substrate 3, 3 mM DTT, 50 μM purified AclHMT (W27F / P8L / V265W), 150 μM purified MpOMT4 (M159V / S142V / W256S), and 50 mM Tris-HCl buffer (pH 7.5). After reacting in a 30 °C water bath in the dark for 20 h, an equal volume of anhydrous methanol was added, and the mixture was allowed to stand at -20 °C for 30 min to quench the reaction. Protein precipitate was removed by centrifugation at 12000 rpm for 30 min, and the supernatant was analyzed by HPLC. Substrate consumption and product formation were detected at dual wavelengths of 215 nm and 260 nm using a Shimadzu C18 column (250 mm × 4.6 mm, 5 μm). The HPLC elution gradient was as follows: 0–4 min 0% B, 4–9 min 0–14% B, 9–16 min 14–30% B, 16–27 min 30–36% B, 27.01–30 min 95% B, and 30.01–34 min 0% B. The mobile phase consisted of ultrapure water containing 0.1% TFA and acetonitrile, and the flow rate was 1 mL / min.

[0077] The reaction formula is as follows:

[0078]

[0079] Example 5: One-pot multi-enzyme cascade stepwise catalytic synthesis of troxerutin

[0080] The enzymatic synthesis of troxerutin involves five steps. The first three steps are hydroxyethylation modifications. Using a cascade reaction of AclHMT (W27F / P8L / V265W) with OsNOMT (L284A), ROMT9 (M184G / W271H), and MpOMT4 (M159V / S142V / W256S), the 7-OH, 3'-OH, and 4'-OH groups of quercetin are hydroxyethylated stepwise to generate 7,3',4'-3HOEt-quercetin. Subsequently, the 3-OH group of 7,3',4'-3HOEt-quercetin is further glucosylated using the glycosyltransferase Sb3GT1 to generate 7,3',4'-3HOEt-quercetin-3-O. The glucose 6'-OH group of the aforementioned product was modified with rhamnosyltransferase CiRhaT-GD4x to generate 7,3',4'-3HOEt-rutin, i.e., troxerutin. To simplify the experimental procedure, all the above step-by-step reactions were carried out in the same reaction system. That is, after the previous step was completed, no intermediate separation or purification was required; the enzyme and substrate for the next step were simply added to the reaction system. After all reactions were completed, the final product was separated and purified. For other monohydroxyethylated and dihydroxyethylated analogs, a similar one-pot multi-enzyme cascade reaction was used. Either FeF3G6"RhaT or CiRhaT-GD4x can be used as the rhamnosyltransferase. It is important to note that for polyhydroxyethylated products, the modification sequence of 7'-OH first, then 3'-OH, and finally 4'-OH must be strictly followed.

[0081] Taking troxerutin as an example, the specific reaction operation is as follows: First, 7-HOEt-quercetin is synthesized based on the AclHMT(W27F / P8L / V265W)-OsNOMT(L284A) cascade reaction in Example 3, and 15 μL of the sample is retained for HPLC analysis. Subsequently, using 7-HOEt-quercetin as a substrate, 100 μM SAH, 10 mM MgCl2, 50 μM purified AclHMT (W27F / P8L / V265W), and 75 μM purified ROMT9 (M184G / W271H) were added to construct a new cascade reaction system of AclHMT(W27F / P8L / V265W)-ROMT9(M184G / W271H) with a total volume of 100 μL. The reaction was continued in a water bath at 30 ℃ in the dark for 20 h to synthesize 7,3'-2HOEt-quercetin. 15 μL of the sample was retained for HPLC analysis. Continuing with 7,3'-2HOEt-quercetin as the substrate, 200 μM SAH, 50 μM purified AclHMT (W27F / P8L / V265W), and 150 μM purified MpOMT4 (M159V / S142V / W256S) were added to construct a new cascade reaction system of AclHMT(W27F / P8L / V265W)-MpOMT4(M159V / S142V / W256S) with a total volume of 105 μL. The reaction was continued in a 30 ℃ water bath in the dark for 20 h to synthesize 7,3',4'-3HOEt-quercetin. After retaining 15 μL of the sample for HPLC analysis, a new reaction system with a total volume of 105 μL was formed by adding UDP-glucose to a final concentration of 1.5 mM, MgCl2 to a final concentration of 10 mM, DTT to a final concentration of 3 mM, purified Sb3GT1 to a final concentration of 50 μM, and Tris-HCl buffer (pH 8.0). This reaction system was incubated in a 45 °C water bath for 2.5 h to synthesize 7,3',4'-3HOEt-quercetin-3-O-glucoside, and 15 μL of this sample was retained for HPLC analysis. Finally, a new reaction system with a total volume of 95 μL was formed by adding UDP-rhamnose to a final concentration of 1.5 mM and purified CiRhaT-GD4x to a final concentration of 1.5 mM, and incubated in a 45 °C water bath for another 2.5 h to finally synthesize troxerutin.An equal volume of anhydrous methanol was added, and the mixture was allowed to stand at -20 °C for 30 min to quench the reaction and then centrifuged. The mixture, along with samples retained after each previous reaction step, was analyzed by HPLC. The overall yield was 91%. The HPLC elution gradient was: 0–4 min 0% B, 4–9 min 0–14% B, 9–16 min 14–30% B, 16–27 min 30–36% B, 27.01–30 min 95% B, and 30.01–34 min 0% B. The mobile phase was ultrapure water containing 0.1% TFA and acetonitrile, with a flow rate of 1 mL / min. The same reaction system was used to scale up the preparation of the target product. Preparative HPLC was used for separation and purification at a flow rate of 3 mL / min. The purified sample was collected and freeze-dried under vacuum to obtain the product (9.3 mg, yield 84%). The NMR and mass spectrometry data of troxerutin are as follows: 1 H NMR (500 MHz, DMSO-d6) δ 12.52 (s, 1H), 7.84 (d, J=2.1 Hz, 1H), 7.70 (dd, J=8.6, 2.1 Hz, 1H), 7.13 (d, J=8.7 Hz, 1H), 6.74 (d, J=2.3 Hz, 1H), 6.38 (d, J=2.2 Hz, 1H), 5.43 (d, J=7.4 Hz, 1H), 5.36 (d, J=4.4Hz, 1H), 5.14 (d, J=4.7 Hz, 1H), 5.10 (d, J=5.8 Hz, 1H), 4.95 (t, J=5.5 Hz, 1H), 4.90 (q, J=5.7 Hz, 2H), 4.51 (d, J=5.3 Hz, 1H), 4.43–4.37 (m, 3H), 4.15–4.04 (m, 6H), 3.76 (tq, J=10.3, 5.5, 4.4 Hz, 7H), 3.39 (q, J=4.3, 3.0 Hz, 1H), 3.31–3.16 (m, 6H), 3.06 (dq, J=9.3, 4.9Hz, 2H), 0.97 (d, J=6.2 Hz, 3H). 13C NMR (125 MHz, DMSO-d6) δ 177.37, 164.54, 160.73, 156.47, 156.35, 150.75, 147.40, 133.54, 122.42, 122.26, 114.22, 112.64, 104.95, 101.16, 100.82, 98.27, 92.77, 76.24, 75.84, 74.02, 73.78, 71.61, 70.42, 70.20, 70.05, 68.16, 67.03, 59.90, 59.41, 59.36, 59.18, 57.91, 17.59.LCMS(ESI) calcd.for C 33 H 42 O 19 [M+H] 1+ 743.2393, obsd.743.2284.

[0082] The reaction formula is as follows:

[0083]

[0084] Example 6: A one-step catalytic cascade of AclHMT (W27F / P8L / V265W) and COMT to produce 3'-hydroxyethylrutin (3'-HOEt-rutin) and 7,3'-dihydroxyethylrutin (7,3'-2HOEt-rutin).

[0085] After achieving efficient enzymatic synthesis of troxerutin and its analogues via a one-pot, multi-enzyme stepwise cascade reaction, we attempted to optimize the reaction conditions by directly using rutin or quercetin-3-O-glucoside as substrates and hydroxyethylating them with methyltransferases. The human catechol O-methyltransferase COMT has a broad substrate spectrum, catalyzing the 3'-OH modification of various catechol substrates and exhibiting strong tolerance to large groups. The hydroxyethylating activity of COMT on rutin and 7-hydroxyethylrutin (7-HOEt-rutin) was tested using a cascade reaction. HPLC analysis revealed that COMT converted these two substrates to 3'-HOEt-rutin and 7,3'-2HOEt-rutin, respectively, with 100% analytical yield.

[0086] The cascade reaction activity assay for rutin and 7-HOEt-rutin consisted of a 100 μL system containing 150 μM SAH, 2.5 mM HOEtI, 1 mM rutin or 7-HOEt-rutin, 10 mM MgCl2, 50 μM purified AclHMT (W27F / P8L / V265W), 75 μM purified COMT, and 50 mM PBS buffer (pH 7.6). After reacting in a 30 °C water bath in the dark for 20 h, an equal volume of anhydrous methanol was added, and the system was incubated at -20 °C for 30 min to quench the reaction. Protein precipitate was removed by centrifugation at 12000 rpm for 30 min, and the supernatant was analyzed by HPLC. Substrate consumption and product formation were detected at dual wavelengths of 215 nm and 260 nm using a Shimadzu C18 column (250 mm × 4.6 mm, 5 μm). The HPLC elution gradient was: 0–4 min 0% B, 4–12 min 0–16% B, 12–23 min 16–32% B, 23.01–26 min 90% B, and 26.01–30 min 0% B. The mobile phases were ultrapure water containing 0.1% TFA and acetonitrile, respectively, at a flow rate of 1 mL / min. The same reaction system was used to scale up the preparation of the target product. Preparative HPLC was used for separation and purification at a flow rate of 3 mL / min. The purified sample was collected and freeze-dried under vacuum to obtain 3'-HOEt-rutin (9 mg, 92% yield) and 7,3'-2HOEt-rutin (9.7 mg, 93% yield). The NMR and mass spectrometry data of 3'-HOEt-rutin are as follows: 1 H NMR (800 MHz, DMSO-d6) δ 12.54 (s, 1H), 10.91 (s, 1H), 9.02 (s, 1H), 7.68 (dd, J=8.5, 2.2 Hz, 1H), 7.52 (d, J=2.2 Hz, 1H), 7.03 (d, J=8.6 Hz, 1H), 6.42 (d, J=2.1 Hz, 1H), 6.21 (d, J=2.1 Hz, 1H), 5.37 (d, J=7.4 Hz, 1H), 5.33 (s, 1H), 5.15–5.08 (m, 2H), 4.93 (t, J=6.1 Hz, 1H), 4.58 (s, 1H), 4.42 (d, J=13.0 Hz, 3H), 4.08 (dp, J=14.9, 5.0 Hz, 2H), 3.77 (q, J=4.7 Hz, 2H), 3.71 (d, J=10.0 Hz, 1H), 3.35–3.18 (m, 7H), 3.09 (t, J=9.0 Hz, 2H), 0.98 (d, J=6.2 Hz, 3H). 13C NMR (200 MHz, DMSO-d6) δ 177.30, 164.07, 161.09, 156.37, 156.25, 149.04, 145.83, 133.50, 122.56, 121.34, 115.54, 112.11, 103.92, 101.15, 1 00.64, 98.63, 93.58, 76.26, 75.66, 73.97, 71.69, 70.47, 70.24, 70.05, 69.68, 68.13, 66.71, 59.50, 17.62.LCMS(ESI) calcd. for C29H34O17 [MH]1- The NMR and mass spectrometry data for 653.1723, obsd.653.1838.7,3'-2HOEt-rutin are as follows: ¹H NMR (800 MHz, DMSO-d6) δ 12.53 (s, ¹H), 8.97 (s, ¹H), 7.71 (d, J=8.5 Hz, ¹H), 7.56 (s, ¹H), 7.04 (d, J=8.6 Hz, ¹H), 6.72 (d, J=2.1 Hz, ¹H), 6.37 (d, J=2.2 Hz, ¹H), 5.39 (d, J=7.0 Hz, ¹H), 4.40 (s, ¹H), 4.10 (ddd, J=20.7, 10.1, 4.9) 13C NMR (200 MHz, DMSO-d6) δ 177.55, 164.64, 160.85, 156.69, 156.45, 149.25, 145.98, 133.86, 122.62, 121.55, 115.76, 112.21, 105.01, 101.20, 100.79, 98.4 0, 92.72, 76.40, 75.85, 74.09, 71.81, 70.60, 70.51, 70.37, 70.21, 69.88, 68.26, 66.91, 59.63, 59.30, 17.76.LCMS(ESI)calcd.for C 31 H 38 O 18 [MH] 1- 697.1985, obsd.697.2029.

[0087] The reaction formula is as follows:

[0088]

[0089] Example 7: Two-step enzymatic synthesis of 4'-hydroxyethyl quercetin-3-O-glucoside and 4'-hydroxyethyl rutin (4'-HOEt-rutin) by cascade catalysis of AclHMT (W27F / P8L / V265W) and GerMIII (Y212W / L222I).

[0090] The flavonoid O-methyltransferase GerMIII from Streptomyces has been reported to be resistant to quercetin-3-O-glucoside. The hydroxyethylation activity of GerMIII on quercetin-3-O-glucoside was tested by a cascade reaction with AclHMT (W27F / P8L / V265W). HPLC detected a 30% analytical yield of the hydroxyethylated product, but the product was mixed, possibly producing both 3'-OH and 4'-OH hydroxyethylated products simultaneously. Since the crystal structure of GerMIII has not yet been reported, homology modeling of GerMIII was performed using the crystal structure of the O-methyltransferase SpnK (PDB: 8iaa) in the spinosad biosynthesis pathway as a template. The obtained GerMIII model was then molecularly docked with SAM and HOEt-SAM, respectively. By comparing the position and morphology of the ligands after docking, a superior model with a similar morphology to the SpnK ligand and lower energy was selected. Using this superior model, the Funclib website was used to calculate the target amino acid with greater catalytic potential. Combining the structural analysis and calculation results, seven single mutations were designed at the Y212, I209, and L222 sites. Based on the activity test results of the mutants, six double mutations were constructed based on the superior single mutations. Among them, Y212W / L222I produced a product with selective hydroxyethyl modification at a single 4'-OH site with an analytical yield of 92%, and was considered the optimal mutant. The conversion rates of the other double mutants to 1 mM substrate under the same experimental conditions were: Y212W / L222M: 45%, Y212W / L222V: 80%, Y212W / I209V: 76%, Y212W / I209L: 0%, and Y212W / I209M: 2%.

[0091] The cascade reaction activity assay consisted of a 100 μL system containing 200 μM SAH, 2.5 mM HOEtI, 1 mM quercetin 3-O-glucoside, 10 mM MgCl2, 50 μM purified AclHMT (W27F / P8L / V265W), 100 μM purified GerMIII (Y212W / L222I), and 50 mM Tris-HCl buffer (pH 7.5). The reaction was carried out in a 30 °C water bath in the dark for 20 h, followed by the addition of an equal volume of anhydrous methanol and incubation at -20 °C for 30 min to quench the reaction. Protein precipitate was removed by centrifugation at 12000 rpm for 30 min, and the supernatant was analyzed by HPLC. Substrate consumption and product formation were detected using a Shimadzu C18 column (250 mm × 4.6 mm, 5 μm) at dual wavelengths of 215 nm and 260 nm. The HPLC elution gradient was: 0-4 min 0% B, 4-12 min 0-16% B, 12-23 min 16-32% B, 23.01-26 min 90% B, and 26.01-30 min 0% B. The mobile phases were ultrapure water containing 0.1% TFA and acetonitrile, and the flow rate was 1 mL / min. The preparative reaction was carried out on a scale-up basis in the same system. After the reaction was completed, UDP-rhamnose (1.5 mM), MgCl2 (10 mM), DTT (3 mM), purified FeF3G6"RhaT (50 μM), and Tris-HCl buffer (pH 8.0) were added to the system to prepare 4'-HOEt-rutin. After quenching the reaction and centrifuging, the product was purified by preparative HPLC at a flow rate of 3 mL / min. The purified sample was collected and freeze-dried under vacuum to obtain the product 4'-HOEt-rutin (8.6 mg, yield 88%). The NMR and mass spectrometry data of 4'-HOEt-rutin are as follows: 1H NMR (800 MHz, DMSO-d6) δ 12.57 (s, 1H), 10.87 (s, 1H), 9.53 (s, 1H), 7.83 (d, J=2.1Hz, 1H), 7.54 (dd, J=8.4, 2.1 Hz, 1H), 6.93 (d, J=8.4 Hz, 1H), 6.43 (d, J = 2.0 Hz, 1H), 6.21 (d, J = 2.1 Hz, 1H), 5.41 (d, J = 7.6 Hz, 1H), 4.40 (s, 4H), 4.03 (t, J = 5.0 Hz, 2H), 3.78 (q, J = 5.2 Hz, 2H), 3.72 (d, J=11.3 Hz, 1H), 3.33 (d, J=7.0 Hz, 4H), 3.29 (d, J=9.0 Hz, 2H), 3.27–3.21 (m, 4H), 3.20 (s, 1H), 3.04 (dt, J=24.7, 9.2 Hz, 2H), 0.97 (d, J=6.2 Hz, 3H). 13 CNMR (200 MHz, DMSO-d6) δ 176.17, 162.95, 160.02, 155.35, 155.31, 148.32, 144.84, 131.90, 121.40, 119.95, 114.06, 113.05, 102.88, 100.04, 99.75 ,97.56,92.66,75.19,74.78,73.04,70.58,69.41,69.22,69.16,69.05,67.13,65.92,58.47,16.53.LCMS(ESI)calcd.for C 29 H 34 O 17 [M+H] 1+ 655.1869, obsd.655.1935.

[0092] The reaction formula is as follows:

[0093]

[0094] The specific embodiments described above further illustrate the purpose, technical solution, and beneficial effects of this application. It should be understood that the above descriptions are merely specific embodiments of this application and are not intended to limit this application. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of this application should be included within the protection scope of this application.

Claims

1. A SAM analog having the structure shown in formula (I): Equation (I).

2. The use of a SAM analog as described in claim 1 as a hydroxyethyl donor.

3. A methyltransferase mutant, comprising: The CNMT methyltransferase mutant, with threonine at position 71 mutated to valine and threonine at position 189 mutated to serine, has its amino acid sequence in GenBank accession number BAB71802.

1. The methyltransferase OsNOMT, which has a leucine mutation at position 284 to alanine, has its amino acid sequence accessed in GenBank as BAM13734.

1. The methyltransferase MpOMT4 is a wild-type methyltransferase with methionine at position 159 mutated to valine, serine at position 142 mutated to valine, and tryptophan at position 246 mutated to serine. The GenBank accession number for the amino acid sequence of wild-type methyltransferase MpOMT4 is AAR09602.

1. The methyltransferase GerMIII, with tyrosine at position 212 mutated to tryptophan and leucine at position 222 mutated to isoleucine, has its amino acid sequence accessed in GenBank as ABB52542.

1.

4. A method for hydroxyethylating a compound, comprising: The compound to be reacted, the SAM analog as described in claim 1, the methyltransferase mutant as described in claim 2, and the pH buffer are mixed to obtain a reaction raw material solution; The reactant solution was subjected to a reaction in the dark to obtain a reaction mixture; The reaction mixture was quenched and purified sequentially to obtain the hydroxyethylated compound; Preferably, the temperature of the light-protected reaction is 20~40℃, and the time of the light-protected reaction is 15~25h; Preferably, the pH buffer solution is at least one of tris(hydroxymethyl)aminomethane hydrochloride solution, alkali metal phosphate solution, alkali metal borate solution, and alkali metal carbonate solution.

5. A method for hydroxyethylation using a cyclic enzyme cascade reaction, comprising: Steps 1) and 2) are carried out simultaneously in the same reaction system. 1) The reaction of SAH with a hydroxyethylating agent is catalyzed by a halide methyltransferase mutant to generate a SAM analog as shown in formula (I); 2) The SAM analog shown in formula (I) reacts with the receptor substrate under the action of a methyltransferase mutant or a methyltransferase to obtain the hydroxyethylated receptor product and the SAH in step 1); The SAH cycle obtained in step 2) is used in the reaction of step 1).

6. The method according to claim 5, wherein, The halide methyltransferase mutant is a halide methyltransferase AclHMT with tryptophan at position 27 mutated to phenylalanine, proline at position 8 mutated to leucine, and valine at position 265 mutated to tryptophan. The amino acid sequence of the wild-type halide methyltransferase AclHMT has the GenBank accession number EAW10780.

1.

7. The method according to claim 5, wherein, When the receptor substrate is rutin or quercetin-3-O-glucoside, the methyltransferase is COMT, whose amino acid sequence has the GenBank accession number AAA68927.1; When the receptor substrate is juglansin, the methyltransferase mutant is the methyltransferase OsNOMT with leucine at position 284 mutated to alanine. The GenBank accession number for the amino acid sequence of the wild-type methyltransferase OsNOMT is BAM13734.

1. When the receptor substrate is a tetrahydroisoquinoline alkaloid, the methyltransferase mutant is a CNMT methyltransferase mutant with threonine at position 71 mutated to valine and threonine at position 189 mutated to serine. The GenBank accession number for the amino acid sequence of the wild-type methyltransferase CNMT is BAB71802.

1. When the receptor substrate is quercetin, the methyltransferase mutant is OsNOMT, a methyltransferase with leucine at position 284 mutated to alanine, and the GenBank accession number for the amino acid sequence of the wild-type methyltransferase OsNOMT is BAM13734.1; or MpOMT4, a methyltransferase with methionine at position 159 mutated to valine, serine at position 142 mutated to valine, and tryptophan at position 246 mutated to serine, and the GenBank accession number for the amino acid sequence of the wild-type methyltransferase MpOMT4 is AAR09602.

1. When the receptor substrate is quercetin-3-O-glucoside, the methyltransferase mutant is a methyltransferase GerMIII with tyrosine at position 212 mutated to tryptophan and leucine at position 222 mutated to isoleucine. The GenBank accession number for the amino acid sequence of the wild-type methyltransferase GerMIII is ABB52542.

1.

8. A method for synthesizing troxerutin, comprising: The first part SAH, hydroxyethylating reagent, first part halide methyltransferase mutant, reducing agent, first methyltransferase mutant, and quercetin are mixed and subjected to the first cascade reaction to obtain the first reaction solution with 7-hydroxyethylated quercetin. The second part SAH, the second part halide methyltransferase mutant, and the second methyltransferase mutant were added to the first reaction solution containing 7-hydroxyethylated quercetin to carry out a second cascade reaction, thereby obtaining a second reaction solution containing di-hydroxyethylated quercetin. The third part SAH, the third part halide methyltransferase mutant, and the third methyltransferase mutant were added to the second reaction solution containing di-hydroxyethylated quercetin to carry out a third cascade reaction, resulting in a third reaction solution containing tri-hydroxyethylated quercetin. The 3-hydroxyethylated quercetin in the third reaction solution was sequentially modified by glucosylation and rhamnosylation to obtain troxerutin.

9. The synthesis method according to claim 8, wherein, The first methyltransferase mutant is OsNOMT, which has a leucine-to-alanine mutation at position 284; the second methyltransferase mutant is ROMT9, which has a methionine-to-glycine mutation at position 184 and a tryptophan-to-histidine mutation at position 271. The NCBI accession number for the amino acid sequence of wild-type methyltransferase ROMT9 is NP_001390411.1; the third methyltransferase mutant is MpOMT4, which has a methionine-to-valine mutation at position 159, a serine-to-valine mutation at position 142, and a tryptophan-to-serine mutation at position 246.

10. The synthesis method according to claim 9, wherein, The halide methyltransferase mutant is AclHMT, which mutates tryptophan at position 27 to phenylalanine, proline at position 8 to leucine, and valine at position 265 to tryptophan. Preferably, the reducing agent is tris(2-carboxyethyl)phosphine hydrochloride, and more preferably, the reducing agent is dithiothreitol.